financial results

The revenues come entirely from CGI's discovery services as its divested biopharma services and clinical lab units were considered discontinued operations.

The firm, which is working to reaccelerate its test validation effort, incurred a loss of $5.4 million, or $.10 per share, slightly above the analysts' consensus estimate.

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

The revenue growth was driven in part by sales generated by Australian reagent maker TGR Biosciences, which Expedeon acquired in May last year.

The firm reported total revenues of $215.4 million, up from $193.9 million in fiscal Q4 2018, but below the consensus Wall Street estimate of $221.0 million.

In its first quarter operating as a public company, the Seattle-based immune sequencing firm more than tripled development revenues and grew sequencing revenues.

The firm brought in $15.8 million during the quarter compared to $8.8 million a year ago, and beating Wall Street expectations.

The company missed the analysts' average estimates on the top and bottom lines, but it raised its full-year 2019 revenue guidance.

Buoyed by a 26 percent increase in test volume, the firm's revenues were $1.2 million for the quarter, compared to $822,000 last year.

The company is delaying the publication of its business and financial update for the first half of 2019 to allow for an ongoing review by its auditors.